Lipocine
LPCN
37 hedge funds and large institutions have $18.6M invested in Lipocine in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 11 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0.34% less ownership
Funds ownership: 1.67% → 1.33% (-0.34%)
12% less funds holding
Funds holding: 42 → 37 (-5)
15% less capital invested
Capital invested by funds: $21.9M → $18.6M (-$3.37M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
74% less call options, than puts
Call options by funds: $451K | Put options by funds: $1.72M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$972K |
| 2 |
DAM
DLD Asset Management
New York
|
+$934K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$565K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$511K |
| 5 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$425K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.98M |
| 2 |
RA
Royce & Associates
New York
|
-$1.43M |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$425K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$353K |
| 5 |
Goldman Sachs
New York
|
-$300K |
LPCN Hedge Fund Activity: Q3 2017 in Review
37 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2017, worth a combined $18.6M — down 15% from $21.9M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LPCN and 6 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $972K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.98M sold.
- 37 institutional investors held Lipocine (LPCN) as of Q3 2017, down from 42 in Q2 2017.
- Funds reported $18.6M of Lipocine stock for Q3 2017, down 15% quarter-over-quarter.
- 6 funds opened new Lipocine positions in Q3 2017 and 11 closed out, a net change of -5 holders.
- The largest Lipocine buyer in Q3 2017 was Renaissance Technologies, an estimated $972K added.
- The largest Lipocine seller in Q3 2017 was Cormorant Asset Management, an estimated $2.98M sold.
Based on aggregated 13F filings for Q3 2017.